LATEST UPDATES » Vol 25, No. 05, May 2020 – Surviving COVID-19: Personal Experience of Dr. J Richard Smith       » Open Source AI-Powered Tool by Tencent for COVID-19 Preliminary Self Evaluation       » COVID-19 and its Impact on a Global and Societal Scale       » Optimal Egg Consumption to Lower Risk of Cardiovascular Disease       » Cohort Analysis of Remdesivir as Antiviral Treatment for COVID-19       » Easing Strain on Healthcare Systems with COVID-19 Patient Management Platform      
Cancer cells are addicted to methionine
Singapore scientists discover a nutrition pathway to stamp out the start of cancer

Scientists have discovered that cancer stem cells, the founder cells of a tumour, have unique nutrient requirements. Unlike the rest of the tumour cells, cancer stem cells are addicted to a type of dietary amino acid – methionine – which is linked to their ability to form tumours.

Methionine is an essential amino acid absorbed from diet for normal cell growth. However, a metabolite produced from it, S-adenosylmethionine (SAM), is involved in the regulation of critical gene functions in cancer stem cells. Importantly, this methionine metabolism pathway is controlled by a critical metabolic enzyme known as MAT2A (methionine adenoyltransferase 2A) that converts methionine to SAM.

This surprising discovery has implications on how one can develop better drugs against cancer. By specifically drugging this metabolic pathway, laboratory models of tumours are more effectively targeted compared to conventional treatment regimes.

The researchers at the Agency for Science, Technology and Research’s (A*STAR) Genome Institute of Singapore (GIS), Bioprocessing Technology Institute (BTI) and oncologists at the National Cancer Centre Singapore (NCCS) published their findings in Nature Medicine.

Dr Tam Wai Leong, the senior author of the study, Group Leader at the GIS and faculty member at Cancer Science Institute of Singapore, explained, “Cancer cells within a tumour are quite different from one another. Like human beings, they have different dietary preferences from each other. Through this study, we discovered that the cancer stem cells are addicted to a particular nutrient – methionine. By blocking the ability of the cancer stem cells to use this amino acid with potential anti-cancer therapeutics, we are able to effectively halt the growth of a tumour.”

“MAT2A is an interesting enzyme that controls the metabolism of cancer cells. From our findings, this enzyme represents an important new drug target, as its inhibition led to the ablation of cancer stem cells. This paves the way for the development of next-generation drugs that target this dependence on methionine,” said Dr Wang Zhenxun, the first author of this study.

The research is supported by A*STAR, and the National Medical Research Council’s Large Collaborative Grant for fighting lung cancer.

Click here for the complete issue.

news Medtec China to return in September with integrated manufacturing resources for the entire high-end medical industry chain
news Joining Forces to Elevate Asia's Healthcare Industry
news 4th Global Feed Summit draws Feed Producers, Technology Providers, Raw Materials Suppliers to Bangkok for Key Discussions
news 2nd China Pharma Digital Innovation Summit to be held in Shanghai

About Us
Available issues
Editorial Board
Letters to Editor
Contribute to APBN
Advertise with Us
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Deborah Seah
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
Copyright© 2020 World Scientific Publishing Co Pte Ltd  •  Privacy Policy